{"title":"用于细菌感染PET成像的新型68ga标记泛素29-41复合物的合成及生物学评价","authors":"Yuhao Jiang, Qianna Wang, Xiaojiang Duan, Junhong Feng, Guangxing Yin, Peiwen Han, Qing Ruan, Ziqing Zhao, Jianyong Jiang, Junbo Zhang","doi":"10.1021/acs.molpharmaceut.5c00988","DOIUrl":null,"url":null,"abstract":"<p><p>The persistent challenge of bacterial infections in clinical practice necessitates the development of precise diagnostic tools capable of differentiating infectious and inflammatory processes. This study presents the development and evaluation of [<sup>68</sup>Ga]Ga-NOTA-UBI 29-41, a novel PET radiotracer designed for specific bacterial infection imaging. The tracer was synthesized through <sup>68</sup>Ga-labeling of a NOTA-conjugated ubiquicidin 29-41 derivative, demonstrating excellent radiochemical properties and good <i>in vitro</i> stability in both saline and mouse serum. <i>In vitro</i> binding assays confirmed specific targeting of <i>Staphylococcus aureus</i>, while <i>in vivo</i> studies in mice models revealed significantly higher uptake in infected versus inflamed muscle tissue (<i>p</i> < 0.01). MicroPET imaging further validated the tracer's ability to selectively accumulate at infection sites, with pharmacokinetic analysis showing predominant renal clearance and rapid blood clearance kinetics. These findings collectively demonstrate the potential of [<sup>68</sup>Ga]Ga-NOTA-UBI 29-41 as a clinically translatable agent for accurate discrimination between bacterial infections and sterile inflammation.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":" ","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Synthesis and Biological Evaluation of a Novel <sup>68</sup>Ga-Labeled Ubiquicidin 29-41 Complex for PET Imaging of Bacterial Infections.\",\"authors\":\"Yuhao Jiang, Qianna Wang, Xiaojiang Duan, Junhong Feng, Guangxing Yin, Peiwen Han, Qing Ruan, Ziqing Zhao, Jianyong Jiang, Junbo Zhang\",\"doi\":\"10.1021/acs.molpharmaceut.5c00988\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The persistent challenge of bacterial infections in clinical practice necessitates the development of precise diagnostic tools capable of differentiating infectious and inflammatory processes. This study presents the development and evaluation of [<sup>68</sup>Ga]Ga-NOTA-UBI 29-41, a novel PET radiotracer designed for specific bacterial infection imaging. The tracer was synthesized through <sup>68</sup>Ga-labeling of a NOTA-conjugated ubiquicidin 29-41 derivative, demonstrating excellent radiochemical properties and good <i>in vitro</i> stability in both saline and mouse serum. <i>In vitro</i> binding assays confirmed specific targeting of <i>Staphylococcus aureus</i>, while <i>in vivo</i> studies in mice models revealed significantly higher uptake in infected versus inflamed muscle tissue (<i>p</i> < 0.01). MicroPET imaging further validated the tracer's ability to selectively accumulate at infection sites, with pharmacokinetic analysis showing predominant renal clearance and rapid blood clearance kinetics. These findings collectively demonstrate the potential of [<sup>68</sup>Ga]Ga-NOTA-UBI 29-41 as a clinically translatable agent for accurate discrimination between bacterial infections and sterile inflammation.</p>\",\"PeriodicalId\":52,\"journal\":{\"name\":\"Molecular Pharmaceutics\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2025-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular Pharmaceutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1021/acs.molpharmaceut.5c00988\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.molpharmaceut.5c00988","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Synthesis and Biological Evaluation of a Novel 68Ga-Labeled Ubiquicidin 29-41 Complex for PET Imaging of Bacterial Infections.
The persistent challenge of bacterial infections in clinical practice necessitates the development of precise diagnostic tools capable of differentiating infectious and inflammatory processes. This study presents the development and evaluation of [68Ga]Ga-NOTA-UBI 29-41, a novel PET radiotracer designed for specific bacterial infection imaging. The tracer was synthesized through 68Ga-labeling of a NOTA-conjugated ubiquicidin 29-41 derivative, demonstrating excellent radiochemical properties and good in vitro stability in both saline and mouse serum. In vitro binding assays confirmed specific targeting of Staphylococcus aureus, while in vivo studies in mice models revealed significantly higher uptake in infected versus inflamed muscle tissue (p < 0.01). MicroPET imaging further validated the tracer's ability to selectively accumulate at infection sites, with pharmacokinetic analysis showing predominant renal clearance and rapid blood clearance kinetics. These findings collectively demonstrate the potential of [68Ga]Ga-NOTA-UBI 29-41 as a clinically translatable agent for accurate discrimination between bacterial infections and sterile inflammation.
期刊介绍:
Molecular Pharmaceutics publishes the results of original research that contributes significantly to the molecular mechanistic understanding of drug delivery and drug delivery systems. The journal encourages contributions describing research at the interface of drug discovery and drug development.
Scientific areas within the scope of the journal include physical and pharmaceutical chemistry, biochemistry and biophysics, molecular and cellular biology, and polymer and materials science as they relate to drug and drug delivery system efficacy. Mechanistic Drug Delivery and Drug Targeting research on modulating activity and efficacy of a drug or drug product is within the scope of Molecular Pharmaceutics. Theoretical and experimental peer-reviewed research articles, communications, reviews, and perspectives are welcomed.